|
|
Article: Schering-Plough Files TEMODAL(R) (temozolomide) EU Marketing Application With EMEA for Newly Diagnosed Glioblastoma Multiforme (Brain Tumors).
- Article from:
- PR Newswire Europe
- Article date:
- November 3, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BRUSSELS, Belgium, November 3 /PRNewswire/ -- Schering-Plough Europe today reported that it has filed an application with the European Medicines Agency (EMEA) seeking centralized Marketing Authorization in the European Union (EU) for the use of TEMODAL(R) (temozolomide) Capsules for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment. Glioblastoma multiforme is a form of brain tumor.
The application provides clinical support for the potential use of TEMODAL in this first-line indication based on efficacy and safety data from a recently completed Phase III study conducted by the ...